Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary highlights a 20% YoY revenue growth and a shift from a net loss to a $50 million net income, indicating strong financial performance. The increase in R&D expenses supports future growth, while improved cash flow reflects efficient management. Despite the lack of strategic and operational updates, the financial results and positive market demand for new therapies suggest a strong positive sentiment. The absence of negative feedback in the Q&A further supports this outlook.
Key Financial Performance
Revenue $300 million, a 20% increase year-over-year, driven by strong demand for our newly launched therapies.
Net Income $50 million, compared to a net loss of $10 million in the same quarter last year, attributed to improved operational efficiencies and higher sales.
Research and Development Expenses $120 million, a 10% increase year-over-year, due to expanded clinical trial activities.
Operating Cash Flow $80 million, a 25% improvement year-over-year, reflecting better working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Ahmad BofA
Barcus Jefferies
Bernstein Institutional
Biliouris Oppenheimer
BofA Securities
Brandon Frith
CEO Director
CEO Dr
CFO Richardson
Chang Robbins
Chief Commercial
Chief Financial
Chief Medical
Citigroup Inc
Commercial Officer
Cowen Research
Development Technical
Director Louise
Division Barcus
Division Brandon
Division Eliana
Division Fleishman
Division Hoang
Executive VP
Inc Research
Klapac President
LLC Research
Louise Rodino
President Research
Research Development
Research Division
Sarepta
VP Chief
SRPT Transcript
Sarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call summary highlights a 20% YoY revenue growth and a shift from a net loss to a $50 million net income, indicating strong financial performance. The increase in R&D expenses supports future growth, while improved cash flow reflects efficient management. Despite the lack of strategic and operational updates, the financial results and positive market demand for new therapies suggest a strong positive sentiment. The absence of negative feedback in the Q&A further supports this outlook.
Sarepta Therapeutics, Inc. (SRPT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-3
Sarepta Therapeutics, Inc. (SRPT) Q4 2025 Earnings Call Transcript
Unknown2-25
The earnings call highlights a mix of positive and negative factors. While there is a 16% revenue increase and promising product developments, significant cost of sales and operating losses are concerning. The Q&A reveals uncertainties in CEO succession and market dynamics, while management's unclear responses further cloud the outlook. The absence of market cap data limits prediction precision, but the neutral sentiment suggests a stock movement within -2% to 2%.
SRPT Slides
SRPT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
